Mirai Advisors and H1 have announced a strategic partnership to deploy AI and enterprise technology in life science organizations.

Most technology value in life sciences is lost between the decision and the delivery. The strategy is rarely the problem. Execution is. Mirai Advisors brings an operator’s judgment to the C-suite, the board and the investment committee — thirty years of running commercial, R&D, manufacturing and IT functions inside Novo Nordisk, Novartis, Takeda, Becton Dickinson and Pfizer. We are independent senior operators, not management consultants. Engagements are scoped to a decision or an outcome, not to a headcount. We take on a small number of clients at a time. WHAT WE DO • Board and C-suite advisory — independent counsel for multinational, PE- and VC-backed leadership teams on technology, data and AI decisions that carry P&L consequence. • Digital and AI transformation — turning AI and digital investment into earnings rather than pilots, with portfolio governance that reports impact and total cost of ownership straight to the C-suite. • Process intelligence in R&D — cycle time is the most under-exploited value lever in pharma R&D, and almost nobody is mining it properly. • Data governance, privacy and compliance — governance that holds up in GxP-regulated, multi-jurisdiction environments. • Digital health, RWE and analytics — connected-health capability built at scale, from smart delivery devices to software as a medical device. • New ventures and investment diligence — an investor’s read on digital health assets, from people who have built them, invested in them and exited them. WHERE WE ARE MOST USEFUL Turnarounds. Investment diligence and valuation. Transformation that has stalled. Executive-level technology oversight. Based between Zurich and New York.